| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_89d397e2fff9dece10c981cc12cb9f06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
2016-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07c0f456fe6af2bacd851fd333b00749
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6902aba308502eed0d3ef70b9534989e |
| publicationDate |
2022-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2902834-T3 |
| titleOfInvention |
Ophthalmic formulations comprising cooperative complexes of low and high molecular weight hyaluronic acid |
| abstract |
Ophthalmic formulations that comprise as active ingredients cooperative hybrid complexes called LX/H-HA, obtainable by heating a mixture of an aqueous solution of at least one fraction (L-X) of keratan at 100-130 °C for 10-30 min. sulfate or chondroitin, said fraction having an average molecular weight ranging from 1-104 to 1-105 Da, and from an aqueous solution of at least one fraction (H-HA) of hyaluronic acid having an average molecular weight of at least 5 times higher than that of L-X and in any case ranging from 5-104Da to 5-106 Da, the weight ratio of L-X to H-HA in the L-X/H-HA complex varies from 0.5 to 2, for use as tear substitutes in the treatment of dry eye syndrome. |
| priorityDate |
2015-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |